Navigation Links
Decision Resources' Forecast of Global Tanezumab Sales Slashed Following FDA Halt of Phase III Studies
Date:10/26/2010

BURLINGTON, Mass., Oct. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that because Phase III trials of Pfizer's tanezumab for the treatment of osteoarthritis pain were halted over U.S. Food & Drug Administration safety concerns, Decision Resources' Pharmaview 2016 global sales forecast for tanezumab has been reduced by $1.2 billion to $200 million. The decision to end the trial was made after a subset of patients in the trial required joint replacement surgery due to worsened conditions.

The discontinuation of the trial is a setback for the drug and a concern for the entire drug class, as tanezumab was the most clinically advanced agent of a family of anti-nerve growth factor (NGF) monoclonal antibodies (MAbs). Anti-NGF MAbs have garnered considerable attention from large pharmaceutical companies for the novel mechanism of action; Sanofi-Aventis (SAR164877), Johnson & Johnson (AMG-403) and Abbott (PG-110) are each in an early-stage program.

"With Lipitor, Celebrex and Viagra all facing patent expiries over the next several years, Pfizer greatly needs new agents to fill the revenue gap," said Pharmaview Analyst Michael Latwis, M.B.A. "Unfortunately, given that approval for osteoarthritis pain—the largest potential market for tanezumab—is highly unlikely, our Pharmaview model does not expect sales to reach anywhere near blockbuster status."

New Pharmaview Platform ReleasedDecision Resources has released a new delivery platform for its Pharmaview product. Pharmaview provides continually updated analysis on more than 2,100 drugs from more than 250 companies, covering 150 product classes and 14 therapy areas—complete with more than 1,200 product-level forecasts.

The new platform includes not only expanded coverage of the biopharmaceutical industry, but enhanced functionality including improved search capabilities an
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Reportlinker Adds Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
2. Mylan to Appeal Court Decision in Generic Paroxetine Hydrochloride CR Case
3. FDAs Just Approved Monthly Drug Treatment, Vivitrol Could Be Game Changer, Says Countrys Largest Drug Treatment Recovery President, CRCs Jerry Rhodes; Provides Addicts One Decision A Month Instead of 30
4. Decision Resources Launches Analogue Tool To Help Pharmaceutical Companies Quickly Assess Market Opportunity
5. Business & Decision North America Announces the Successful Go-Live of Microsoft Dynamics AX at DeVilbiss Healthcare
6. Wise Sky Highlights Their Disappointment at Emergents Decision Not to Enter the China Market
7. Decision Resources Competitive Landscape Seminar Series: Biologics and Biosimilars on September 14, 2010 Will Help Pharmaceutical Companies Understand Market Opportunities for Biologics and Biosimilars
8. FDA Issues Assessments of the 510(k) Program and Use of Science in Decision-Making
9. Medco CEO to Present at the Sanford C. Bernstein & Co., LLC 26th Annual Strategic Decisions Conference 2010
10. Abbott Chairman and CEO Miles D. White to Present at Sanford Bernstein Strategic Decisions Conference
11. HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  Medical ... laboratory which specializes in high complexity, state-of-the-art, ... is now offering new Cystic Fibrosis Testing ... generation DNA sequencing platforms. Cystic ... inherited multisystem disorder that affects the respiratory, ...
(Date:10/22/2014)... FAIRFIELD, N.J. , Oct. 22, 2014 /PRNewswire/ ... a major transformation in the pain market, according ... Pain Insights, Inc., a firm providing market research ... management. Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... a scheduling change for hydrocodone combination products from ...
(Date:10/22/2014)... October 22, 2014 Investor-Edge has ... (NASDAQ: FOLD ), Progenics Pharmaceuticals Inc. (NASDAQ: ... THLD ), Idera Pharmaceuticals Inc. (NASDAQ: ... research on these five companies can be accessed at: ... 2014, the NASDAQ Composite ended at 4,419.48, up 2.40%, ...
Breaking Medicine Technology:Medical Diagnostic Laboratories, L.L.C. Institute for Biomarker Research Announces New Prenatal Cystic Fibrosis Tests 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5
... and VANCOUVER, April 26, 2007,/PRNewswire-FirstCall/ - Angiotech ... medical device company, announced that,the two-year data ... Wrap(TM) Paclitaxel-Eluting Mesh ("Vascular Wrap(TM)"),will be presented ... The,two-year study examined the safety and efficacy ...
... 26, 2007 - A new study published ... ("A National Survey of,Physician-Industry Relationships") on the ... the need for,profession-wide and public policy reforms ... that the existing,voluntary PhRMA (Pharmaceutical Research and ...
Cached Medicine Technology:Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 2Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 3Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 4Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 5Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 6Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 7Ties Between Physicians and Drug Companies Still Too Strong: the,Prescription Project Offers Solutions to Prevent Conflicts of,Interest 2
(Date:10/25/2014)... TASC (Total Administrative Services Corporation), ... account management services, announces the release of four ... taxes, reduce administrative workload, and lessen liability. ... the efficient handling of complex, time-sensitive, and labor-consuming ... meets their goals and objectives. The four Suites ...
(Date:10/25/2014)... 2014 QueenBeeTickets.com has a variety of ... at affordable prices. Bob Seger & The Silver Bullet ... Nationwide Arena are going on sale October 25 and ... to browse the selection of tickets for Bob ... The famous singer is touring North America beginning next ...
(Date:10/25/2014)... October 25, 2014 Mesothelioma researchers are ... to receive pemetrexed (Alimta), after his combination drug therapy ... full story , just posted on the Surviving Mesothelioma ... Tokushukai Medical Center in Japan suggests that “maintenance therapy” ... patients who cannot tolerate higher doses of cisplatin. ...
(Date:10/25/2014)... Reinberg HealthDay Reporter FRIDAY, ... common cold sores -- herpes simplex -- might increase the ... In fact, being a carrier of certain antibodies to ... researchers found. "The identification of a treatable cause ... breakthrough," said lead researcher Dr. Hugo Lovheim, an associate professor ...
(Date:10/25/2014)... News) -- A large influx of international aid is ... tens of thousands of deaths from the widening Ebola ... Using a specially designed mathematical model, the researchers ... just one densely populated county of hard-hit Liberia -- ... The researchers said that if international aid isn,t ...
Breaking Medicine News(10 mins):Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2
... and television that anger causes// the cardiac arrest of ... Yale University researchers have found out that sudden strong ... in the heart to twitch. This may be especially ... although seemingly healthy people my also be affected. ...
... Surrey, UK, had developed a new// drug that will boost ... is made of a compound called CX717, and it is ... This drug had showed effectiveness in increasing memeory, alertness, increasing ... who sleep less. ,The drug was given to ...
... had successfully created a new breed of mice that can ... for themselves.//, ,The reactive oxygen of the free radicals ... to poor health and even death. The new research may ... radical theory of ageing. ,The new mice created ...
... may lead to babies born with deformed prostate glands.//, ... out that prostate deformities can happen if the pregnant ... The pills contain ostrogen like chemiclasthat are alos present ... can cause prostate cancer or bladder diseases later in ...
... study that looked into the smoking habit of 6654 people ... that giving up smoking do causes weight gain, but the ... population under study was measured for effect of giving up ... when the age group was 20 to 44yrs, and was ...
... levels of blood marker for inflammation that can //lead to ... say that it may be good for the health of ... man will have a close family, a good group of ... the workplace, or the neighbors, or a religious organization. ...
Cached Medicine News:
... Worlds First Solid-State Three-Color Photocoagulator.,Retinal physicians ... purchase over 3,000 Lumenis multi-color photocoagulators.,For ... practice, the Novus Varia integrates green, ... a single, compact system that supports ...
... rings, Type 14, 14A and 14C have been ... diameters to accommodate the variations in the size ... capsular tension rings are designed to stabilize the ... a large panel of U.S. ophthalmologists. For ...
Hannum rongeur/grasper with teth in jaws and non-locking design....
Heavy Duty Locking Pliers...
Medicine Products: